Featured

Status

Health Topics

Any Category
Clear Filters

Search Clinical Trials

400 Results
Active, Not Recruiting
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
HPV is found in the cancer cells of more than half the patients with certain types of cancer, suggesting that it may play a role in causing the cancer. The …
Baylor Role: Lead Sponsor
Completed
Complementary Combination Therapy for Cocaine Dependence
During a screening session participants will provide buccal swab for genetics testing, as preliminary data shows that effects of cocaine and of doxazosin are impacted significantly by the genotype at …
Baylor Role: Lead Sponsor
Completed
Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
This is a Phase 1/2, open-label, single-center study to determine safety and tolerability of Ceftaroline in pediatric subjects 1 to 17 years of age (inclusive) with signs and symptoms of …
Baylor Role: Lead Sponsor
Completed
Chronic Hypertension and Pregnancy (CHAP) Project
During pregnancy, chronic hypertension (CHTN) is the most common major medical disorder encountered, occurring in 2-6%. The substantial negative effect of CHTN on pregnancy includes a consistent 3- to 5-fold …
Baylor Role: Collaborator
Completed
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
FAST-MAS addresses an important problem and critical barrier to progress in Mood and Anxiety Spectrum Disorders and if the aims of the project are achieved, FAST-MAS could shift scientific knowledge, …
Baylor Role: Collaborator
Withdrawn
Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial
Research Design and Methods: The study will be a multicenter, randomized, controlled, clinical trial comparing the anti-seizure effect of parenteral and/or oral labetalol (n = 4000) versus parenteral (intravenous or …
Baylor Role: Lead Sponsor
Completed
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
The standard of care in patients receiving rituximab is to give the dose slowly and gradually increase the rate of rituximab until the full dose is given, which may take …
Baylor Role: Lead Sponsor
Terminated
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
This pilot study investigates clinical benefit of four 28-day cycles of sertraline in low-risk MDS patients. Participants will receive 100mg of oral sertraline daily. The study will also evaluate potential …
Baylor Role: Collaborator
Completed
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Patients with primary or recurrent low/intermediate-risk papillary urothelial carcinoma of the bladder will undergo resection of all but one marker lesion, measuring at least 6mm but no greater than 10mm, …
Baylor Role: Lead Sponsor
Completed
Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics
The purpose of the study is to determine the comparative effectiveness of a provider-only intervention and a parent plus provider intervention to increase initiation of HPV vaccination among male and …
Baylor Role: Collaborator